Skip to content

Guardant Health

US · GH #820 by market cap Listed 2018
145.83 +0.24 +0.16%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions decreased by 3 in the most recent period (2026/Q4).
  • Total institutional ownership fell 0.7 percentage points.

Ownership vs. money flow

Diverging

Institutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
100.39% -0.70pp
Institutions
786 -3
As of
2026/Q4 vs. prior period

Holder types

Mutual Fund74.64%
Hedge Fund15.44%
VC/PE Fund3.93%
Individual/Insider3.45%
Public Company2.48%
Government Pension Fund1.43%
Sovereign Wealth Fund1.15%
Private Company0.79%
Insurance Company0.30%

Top holders as of 2026-09-30

BlackRock 5.92% · 8.00M sh
T. Rowe Price Group, Inc. 5.34% · 7.22M sh
FMR 5.32% · 7.19M sh
Vanguard Capital Management, LLC 4.93% · 6.67M sh
Vanguard Portfolio Management, LLC 3.94% · 5.34M sh
Invesco Ltd. 3.07% · 4.11M sh
Two Sigma Investments, LP 2.26% · 3.06M sh
Franklin Resources 2.19% · 2.96M sh
Capital Research 2.17% · 2.94M sh
Deep Track Capital, LP 2.07% · 2.81M sh
Columbia Management Investment Advisers, LLC 1.97% · 2.66M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 25 buys · 23 sells

NameRoleStake
Helmy Eltoukhy Co-Founder, Co-CEO & Chairman 1.69%
AmirAli Talasaz Co-Chief Executive Officer 1.39%
Darya Chudova Chief Technology Officer 0.06%
Craig Eagle Former Chief Medical Officer 0.05%
Christopher Freeman Chief Commercial Officer of Oncology 0.05%
Michael Bell Chief Financial Officer 0.04%
Kumud Kalia Chief Information Officer 0.03%
John Saia Chief Legal Officer 0.03%
Vijaya Gadde Independent Director 0.02%
Terilyn Monroe Chief Human Resources Officer 0.02%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-11 Alex Azar Independent Director Derivative Exercise and Retained +138 --
2026-11-08 Kevin Sayer Director Other Derivative Acquisition +3,149 --
2026-11-08 Robert Parks Senior VP, Principal Accounting Officer & Chief Accounting Officer Other Derivative Acquisition +18,893 --
2026-11-01 Kevin Sayer Director Initial Statement of Beneficial 0 --
2026-11-01 Robert Parks Senior VP, Principal Accounting Officer & Chief Accounting Officer Initial Statement of Beneficial 0 --
2026-10-20 Roberto Mignone Independent Director Derivative Exercise and Retained +264 --
2026-10-16 Manuel Hidalgo Medina Independent Director Derivative Exercise and Retained +232 --
2026-10-15 Musa Tariq Independent Director Derivative Exercise and Sale -116 $165.88
2026-10-15 Musa Tariq Independent Director Intent to Sell (Form 144) -116 $165.88
2026-10-14 Musa Tariq Independent Director Derivative Exercise and Retained +134 --
2026-10-13 Alex Azar Independent Director Open Market Disposition -69 $159.89
2026-10-11 Alex Azar Independent Director Derivative Exercise and Retained +137 --
2026-09-30 Kumud Kalia Chief Information Officer Derivative Exercise and Sale -3,067 $174.75
2026-09-30 Kumud Kalia Chief Information Officer Derivative Exercise and Retained +2,979 --
2026-09-30 Helmy Eltoukhy Co-Founder, Co-CEO & Chairman Derivative Exercise and Sale -18,515 $174.75–178.36
2026-09-30 Helmy Eltoukhy Co-Founder, Co-CEO & Chairman Derivative Exercise and Retained +18,015 --
2026-09-30 Michael Bell Chief Financial Officer Derivative Exercise and Sale -3,914 $174.75
2026-09-30 Michael Bell Chief Financial Officer Derivative Exercise and Retained +3,366 --
2026-09-30 AmirAli Talasaz Co-Chief Executive Officer Derivative Exercise and Sale -18,515 $174.75–178.36
2026-09-30 AmirAli Talasaz Co-Chief Executive Officer Derivative Exercise and Retained +18,015 --

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:17 · For reference only, not investment advice and not tailored to your situation.

Guardant Health discussion 0 comments

Add a comment